Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells
June 19th, 2018
6.7K views
Here we describe a scalable method, using a simple combination of Activin A and lentivirus-mediated Id1-overexpression, to generate first heart field-like cardiac progenitors and ventricular-like cardiomyocytes from human pluripotent stem cells.
Overview
This article presents a scalable method for generating cardiac progenitors and cardiomyocytes from human pluripotent stem cells using Activin A and Id1-overexpression. The technique allows for the production of cells with defined heart field origins, suitable for various research applications.
Key Study Components
Area of Science
- Cardiac biology
- Stem cell research
- Cell-based therapies
Background
- Cardiac progenitors are essential for heart development.
- Human pluripotent stem cells can differentiate into various cardiac cell types.
- Current methods for generating cardiomyocytes can be complex and inefficient.
- Activin A and Id1-overexpression provide a novel approach to enhance cardiac differentiation.
Purpose of Study
- To develop a simple and scalable method for generating cardiac progenitors.
- To produce ventricular-like cardiomyocytes from human pluripotent stem cells.
- To facilitate research in developmental biology and cardiac disease modeling.
Methods Used
- Coating wells of a 96-well plate with a coating reagent.
- Detaching pluripotent stem cells using a dissociation reagent.
- Neutralizing the dissociation reagent with PBS containing calcium and magnesium.
- Transferring cell suspensions for subsequent viral infection steps.
Main Results
- Successfully generated cardiac progenitors with defined origins.
- Produced ventricular-like cardiomyocytes suitable for research.
- Demonstrated the scalability of the method.
- Highlighted potential applications in cell-based therapy and disease modeling.
Conclusions
- The method provides a reliable approach for cardiac cell generation.
- It opens avenues for further research in cardiac biology.
- Future studies can explore the therapeutic potential of generated cells.
Frequently Asked Questions
What are cardiac progenitors?
Cardiac progenitors are precursor cells that can differentiate into various cardiac cell types, essential for heart development.
How does this method improve upon existing techniques?
This method simplifies the process of generating cardiac cells and enhances scalability, making it more accessible for research.
What applications can the generated cells be used for?
The cells can be used in developmental biology studies, cell-based therapies, and modeling cardiac diseases.
Who conducted the study?
The study was conducted by Sean Spiering and Michael Yu from the laboratory of the principal investigator.
What is the significance of using human pluripotent stem cells?
Human pluripotent stem cells have the potential to differentiate into any cell type, making them valuable for regenerative medicine and research.
What role does Activin A play in this method?
Activin A is used to promote the differentiation of pluripotent stem cells into cardiac progenitors.
Executive Industry Relevance
This protocol enables scalable generation of defined cardiac progenitors and ventricular-like cardiomyocytes from human pluripotent stem cells, addressing a critical need for reproducible, heart field-specific cellular models in early discovery. By leveraging Id1 overexpression and Activin A signaling, the method supports mechanistic de-risking of cardiac targets and provides a translational bridge for preclinical validation of therapeutic candidates. The cryopreservable nature of the progenitors enhances workflow flexibility and enterprise-scale assay readiness.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in a defined first heart field-like progenitor system, clarifying pathway-specific drug effects.
- Operational Value: Provides a renewable source of ventricular-like cardiomyocytes (~70-90% efficiency) for consistent target engagement assays.
- Predictive Value: Supports predictive confidence in lead identification by modeling human ventricular physiology and reducing mechanistic ambiguity.
Screening & Assay Development
- Scientific Value: Generates cryopreservable progenitors that can be differentiated into beating cardiomyocytes by Day 25, enabling longitudinal compound screening.
- Operational Value: Standardizes cell preparation through defined seeding densities (20,000 viable cells/well) and puromycin selection, improving assay reproducibility.
- Scalability: Uses 96-well plate format compatible with automated liquid handling and high-throughput screening platforms.
Translational & Preclinical Research
- Translational Continuity: Produces ventricular-like cardiomyocytes expressing MYL2 and IRX4 after Day 15, aligning with preclinical safety pharmacology models.
- Risk-Adjusted Advancement: Enables early detection of cardiotoxicity signals through action potential profiling and contraction metrics.
- Disease Modeling: Supports cardiac disease modeling studies requiring human ventricular subtypes with defined developmental origin.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead optimization to preclinical cardiotoxicity assessment, providing a human-relevant system for ventricular-specific mechanism probing.
- Discovery Biology: Supports hypothesis testing of cardiac developmental pathways via Id1-dependent progenitor specification.
- Screening: Delivers assay-ready ventricular-like cardiomyocytes with quantifiable beating onset (Day 12) and action potential maturation (Day 25).
- Analytics: Enables quantitative readouts including mRNA expression (MYL2, IRX4), electrophysiological traces, and contractile function for compound comparison.
- Translational Research: Connects discovery-phase progenitor generation to preclinical ventricular phenotype assessment.
- Enterprise Reuse: Cryopreservation protocol allows banking of FHF-L progenitors for on-demand differentiation across projects and sites.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in cardiac target validation through defined heart field-origin cells.
- Operational Value: Standardizes differentiation via timed medium changes and selection steps, improving lot-to-lot consistency.
- Strategic Value: Improves go/no-go decisions by providing early human ventricular phenotype data, reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on ventricular-specific safety and efficacy signals.
Implementation Considerations
- Requires expertise in lentiviral transduction, stem cell culture, and cardiac differentiation protocols.
- Needs access to automated cell counters, centrifuges, cryopreservation equipment, and electrophysiology setups for functional validation.
- Demands cross-team standardization of timing (e.g., Day 0 induction, puromycin selection duration) to ensure progenitor quality.
- Adaptation to other model systems may require optimization of Activin A concentration and Id1 expression levels.
- Practical limitation: Efficiency depends on achieving Id1 mRNA expression >0.005-fold GAPDH in starting hPSC lines, necessitating pre-screening.
Biopharma FAQs
Why does quantifying Id1 mRNA expression matter for target validation?
Only hPSC lines expressing Id1 mRNA at levels greater than 0.005-fold GAPDH are used for differentiation, ensuring progenitor specification fidelity and reducing variability in downstream cardiac assays.
How does isolating the effect of Activin A fit the discovery pipeline?
Activin A is used as a specifying cue in induction medium to drive first heart field-like progenitor formation, enabling researchers to test its role in pathway-specific target engagement.
What do quantitative dependent variable measurements of MYL2 and IRX4 enable?
Increased mRNA expression of ventricular-specific markers MYL2 and IRX4 after Day 15 confirms ventricular-like cardiomyocyte identity, supporting target-specific phenotype assessment.
Why do replication requirements matter for cross-functional collaboration?
The protocol defines precise timing for medium changes, dissociation, and replating steps, allowing consistent generation of cryopreservable FHF-L progenitors across laboratories and projects.
What statistical analysis capabilities are required before implementing this method in screening?
Teams must be able to quantify beating onset (Day 12), action potential characteristics (Day 25), and marker expression to statistically compare compound effects on ventricular-like cardiomyocytes.
Chapters in this video
0:04
Title
0:44
Infection with Id1 Virus
2:58
Differentiation of hPSCs into Cryopreservable First Heart Field-like Cardiac Progenitors (FHF-L CPs)
4:38
FHF-L CP Differentiation into Ventricular-like Cardiomyocytes
6:28
Use of Activin A and Lentivirus-mediated Id1 Overexpression to Generate Ventricular-like Cardiomyocytes
8:12
Conclusion
